LCK and neoplasm: Since Compound 182 also enhanced the TCR-induced activation and proliferation of Lck-Cre;Ptpn2fl/fl CD8+ T cells ex vivo (Fig. 2a, c) we surmise that the enhanced repression of tumor growth may be attributed to the inhibition of PTP1B in PTPN2-deficient T cells.